Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors (Q24337334)

Enrique A Mesri

0 references

Gabriel Rabinovich

Gabriel A Rabinovich

0 references

Diego O Croci

Diego O Croci

0 references

Marta A Toscano

Marta A Toscano

0 references

Juan P Cerliani

Juan P Cerliani

0 references

author name string

Tomas Dalotto-Moreno

0 references

Santiago P Méndez-Huergo

0 references

Ivan D Mascanfroni

0 references

Sebastián Dergan-Dylon

0 references

Julio J Caramelo

0 references

Juan J García-Vallejo

0 references

Jing Ouyang

0 references

Melissa R Junttila

0 references

Carlos Bais

0 references

Mariana Salatino

Activation of human endothelial cells by tumor necrosis factor-α results in profound changes in the expression of glycosylation-related genes

0 references

language of work or name

English

0 references

publication date

13 February 2014

0 references

published in

Cell

0 references

volume

156

0 references

issue

0 references

page(s)

744-58

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Online nanoliquid chromatography–mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Dissociation of the carbohydrate-binding and splicing activities of galectin-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Glycosylation in cellular mechanisms of health and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Autocrine VEGF signaling is required for vascular homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Metabolism, cell surface organization, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

PlGF blockade does not inhibit angiogenesis during primary tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Glycomics Hits the Big Time

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Basic and therapeutic aspects of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-3 induces endothelial cell morphogenesis and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Suppression of tumor growth and metastasis in Mgat5-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-1 in melanoma biology and related neo-angiogenesis processes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Alpha2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

A secreted type of beta 1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Developmental and pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Tumor cells secrete galectin-1 to enhance endothelial cell activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

Galectin-1: a link between tumor hypoxia and tumor immune privilege

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021

A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.CELL.2014.01.043

7 January 2021